# OnCo record disitamab-vedotin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/disitamab-vedotin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "disitamab-vedotin" ;
  schema:name "Disitamab vedotin"@en ;
  schema:description "Disitamab vedotin is a Chinese HER2 ADC approved for gastric and bladder cancer, now in global trials with Pfizer."@en ;
  schema:url <https://onco.cc/drugs/disitamab-vedotin/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Disitamab%20vedotin> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  onco:approval "China 2021: HER2+ gastric cancer; HER2-expressing urothelial cancer" ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/urothelial/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/remegen/>, <https://onco.cc/companies/pfizer/> ;
  onco:terms <https://onco.cc/terms/mc-vc-pabc/> ;
  onco:trials <https://onco.cc/trials/nct06155396/>, <https://onco.cc/trials/nct06155383/>, <https://onco.cc/trials/nct06227117/>, <https://onco.cc/trials/nct06389006/>, <https://onco.cc/trials/nct06003231/>, <https://onco.cc/trials/nct06221748/>, <https://onco.cc/trials/nct06178159/>, <https://onco.cc/trials/nct06378242/>, <https://onco.cc/trials/nct06157892/>, <https://onco.cc/trials/nct07315750/>, <https://onco.cc/trials/nct05911295/>, <https://onco.cc/trials/nct06417554/>, <https://onco.cc/trials/nct06966453/>, <https://onco.cc/trials/nct06642545/>, <https://onco.cc/trials/nct04879329/> .